Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

Daniel F. Martin, Michael Klein, Julia Haller, Anthony Adamis, Evangelos Gragoudas, Joan Miller, Mark Blumenkrantz, Morton F Goldberg, Lawrence Yannuzzi, Dwight Henninger, Laurie B. Wiegand, Long Shiuh Chen, Daniel W. Drolet, Stanley C. Gill, Jerry Bill, Blake Tomkinson, R. A. Bendele, Denis O'Shaughnessy, David R. Guyer, Samir Patel

Research output: Contribution to journalArticle

Abstract

Background: Recent studies have suggested that vascular endothelial growth factor (VEGF) is an important stimulus for the growth of new blood vessels in the eye. Anti-VEGF therapy is thus a potential treatment for exudative macular degeneration and diabetic retinopathy. Methods: Previously described animal models of vascular leakage and ocular neovascularization, including the Miles assay, the rat corneal angiogenesis model, and the mouse retinopathy of prematurity (ROP) model, were used to study this drug. After these studies, a phase 1A single ascending dose study of intravitreal injections of the drug was performed in 15 patients with subfoveal choroidal neovascularization secondary to exudative age-related macular degeneration (AMD). Results: The Miles assay model showed almost complete attenuation of VEGF-mediated vascular leakage following addition of EYE001, and the corneal angiogenesis model also showed a significant reduction in neovascularization with EYE001. The ROP model showed inhibition of 80% of the retinal neovascularization compared with controls (P = 0.0001). The phase 1A safety study of patients with exudative AMD showed no significant safety issues related to the drug. Ophthalmic evaluation revealed that 80% of patients showed stable or improved vision 3 months after treatment and that 27% of eyes demonstrated a three-line or greater improvement in vision on the Early Treatment for Diabetic Retinopathy Study chart at this time. Conclusion: Anti-VEGF therapy is a promising new avenue for the treatment of neovascular diseases of the eye, including exudative macular degeneration and diabetic retinopathy. Preclinical data from studies with EYE001 support clinical evaluation of its efficacy in such diseases. This report is the first to describe administration of anti-VEGF therapy in humans for exudative macular degeneration and shows the safety of such therapy for single injections. Further clinical studies are necessary to determine the safety of multiple intravitreal injections of EYE001 and larger studies are needed to prove the efficacy of this novel, potentially therapeutic agent for neovascular AMD.

Original languageEnglish (US)
Pages (from-to)143-152
Number of pages10
JournalRetina
Volume22
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Diabetic Retinopathy
Corneal Neovascularization
Blood Vessels
Retinopathy of Prematurity
Intravitreal Injections
Therapeutics
Safety
Pharmaceutical Preparations
Retinal Neovascularization
Choroidal Neovascularization
Eye Diseases
Patient Safety
Animal Models
Injections
Growth

Keywords

  • Age-related macular degeneration
  • Angiogenesis
  • Pharmacologic intervention
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. / Martin, Daniel F.; Klein, Michael; Haller, Julia; Adamis, Anthony; Gragoudas, Evangelos; Miller, Joan; Blumenkrantz, Mark; Goldberg, Morton F; Yannuzzi, Lawrence; Henninger, Dwight; Wiegand, Laurie B.; Chen, Long Shiuh; Drolet, Daniel W.; Gill, Stanley C.; Bill, Jerry; Tomkinson, Blake; Bendele, R. A.; O'Shaughnessy, Denis; Guyer, David R.; Patel, Samir.

In: Retina, Vol. 22, No. 2, 2002, p. 143-152.

Research output: Contribution to journalArticle

Martin, DF, Klein, M, Haller, J, Adamis, A, Gragoudas, E, Miller, J, Blumenkrantz, M, Goldberg, MF, Yannuzzi, L, Henninger, D, Wiegand, LB, Chen, LS, Drolet, DW, Gill, SC, Bill, J, Tomkinson, B, Bendele, RA, O'Shaughnessy, D, Guyer, DR & Patel, S 2002, 'Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration', Retina, vol. 22, no. 2, pp. 143-152. https://doi.org/10.1097/00006982-200204000-00002
Martin, Daniel F. ; Klein, Michael ; Haller, Julia ; Adamis, Anthony ; Gragoudas, Evangelos ; Miller, Joan ; Blumenkrantz, Mark ; Goldberg, Morton F ; Yannuzzi, Lawrence ; Henninger, Dwight ; Wiegand, Laurie B. ; Chen, Long Shiuh ; Drolet, Daniel W. ; Gill, Stanley C. ; Bill, Jerry ; Tomkinson, Blake ; Bendele, R. A. ; O'Shaughnessy, Denis ; Guyer, David R. ; Patel, Samir. / Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. In: Retina. 2002 ; Vol. 22, No. 2. pp. 143-152.
@article{418dfa95d6994a7bb153f606435464bc,
title = "Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration",
abstract = "Background: Recent studies have suggested that vascular endothelial growth factor (VEGF) is an important stimulus for the growth of new blood vessels in the eye. Anti-VEGF therapy is thus a potential treatment for exudative macular degeneration and diabetic retinopathy. Methods: Previously described animal models of vascular leakage and ocular neovascularization, including the Miles assay, the rat corneal angiogenesis model, and the mouse retinopathy of prematurity (ROP) model, were used to study this drug. After these studies, a phase 1A single ascending dose study of intravitreal injections of the drug was performed in 15 patients with subfoveal choroidal neovascularization secondary to exudative age-related macular degeneration (AMD). Results: The Miles assay model showed almost complete attenuation of VEGF-mediated vascular leakage following addition of EYE001, and the corneal angiogenesis model also showed a significant reduction in neovascularization with EYE001. The ROP model showed inhibition of 80{\%} of the retinal neovascularization compared with controls (P = 0.0001). The phase 1A safety study of patients with exudative AMD showed no significant safety issues related to the drug. Ophthalmic evaluation revealed that 80{\%} of patients showed stable or improved vision 3 months after treatment and that 27{\%} of eyes demonstrated a three-line or greater improvement in vision on the Early Treatment for Diabetic Retinopathy Study chart at this time. Conclusion: Anti-VEGF therapy is a promising new avenue for the treatment of neovascular diseases of the eye, including exudative macular degeneration and diabetic retinopathy. Preclinical data from studies with EYE001 support clinical evaluation of its efficacy in such diseases. This report is the first to describe administration of anti-VEGF therapy in humans for exudative macular degeneration and shows the safety of such therapy for single injections. Further clinical studies are necessary to determine the safety of multiple intravitreal injections of EYE001 and larger studies are needed to prove the efficacy of this novel, potentially therapeutic agent for neovascular AMD.",
keywords = "Age-related macular degeneration, Angiogenesis, Pharmacologic intervention, Vascular endothelial growth factor",
author = "Martin, {Daniel F.} and Michael Klein and Julia Haller and Anthony Adamis and Evangelos Gragoudas and Joan Miller and Mark Blumenkrantz and Goldberg, {Morton F} and Lawrence Yannuzzi and Dwight Henninger and Wiegand, {Laurie B.} and Chen, {Long Shiuh} and Drolet, {Daniel W.} and Gill, {Stanley C.} and Jerry Bill and Blake Tomkinson and Bendele, {R. A.} and Denis O'Shaughnessy and Guyer, {David R.} and Samir Patel",
year = "2002",
doi = "10.1097/00006982-200204000-00002",
language = "English (US)",
volume = "22",
pages = "143--152",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

AU - Martin, Daniel F.

AU - Klein, Michael

AU - Haller, Julia

AU - Adamis, Anthony

AU - Gragoudas, Evangelos

AU - Miller, Joan

AU - Blumenkrantz, Mark

AU - Goldberg, Morton F

AU - Yannuzzi, Lawrence

AU - Henninger, Dwight

AU - Wiegand, Laurie B.

AU - Chen, Long Shiuh

AU - Drolet, Daniel W.

AU - Gill, Stanley C.

AU - Bill, Jerry

AU - Tomkinson, Blake

AU - Bendele, R. A.

AU - O'Shaughnessy, Denis

AU - Guyer, David R.

AU - Patel, Samir

PY - 2002

Y1 - 2002

N2 - Background: Recent studies have suggested that vascular endothelial growth factor (VEGF) is an important stimulus for the growth of new blood vessels in the eye. Anti-VEGF therapy is thus a potential treatment for exudative macular degeneration and diabetic retinopathy. Methods: Previously described animal models of vascular leakage and ocular neovascularization, including the Miles assay, the rat corneal angiogenesis model, and the mouse retinopathy of prematurity (ROP) model, were used to study this drug. After these studies, a phase 1A single ascending dose study of intravitreal injections of the drug was performed in 15 patients with subfoveal choroidal neovascularization secondary to exudative age-related macular degeneration (AMD). Results: The Miles assay model showed almost complete attenuation of VEGF-mediated vascular leakage following addition of EYE001, and the corneal angiogenesis model also showed a significant reduction in neovascularization with EYE001. The ROP model showed inhibition of 80% of the retinal neovascularization compared with controls (P = 0.0001). The phase 1A safety study of patients with exudative AMD showed no significant safety issues related to the drug. Ophthalmic evaluation revealed that 80% of patients showed stable or improved vision 3 months after treatment and that 27% of eyes demonstrated a three-line or greater improvement in vision on the Early Treatment for Diabetic Retinopathy Study chart at this time. Conclusion: Anti-VEGF therapy is a promising new avenue for the treatment of neovascular diseases of the eye, including exudative macular degeneration and diabetic retinopathy. Preclinical data from studies with EYE001 support clinical evaluation of its efficacy in such diseases. This report is the first to describe administration of anti-VEGF therapy in humans for exudative macular degeneration and shows the safety of such therapy for single injections. Further clinical studies are necessary to determine the safety of multiple intravitreal injections of EYE001 and larger studies are needed to prove the efficacy of this novel, potentially therapeutic agent for neovascular AMD.

AB - Background: Recent studies have suggested that vascular endothelial growth factor (VEGF) is an important stimulus for the growth of new blood vessels in the eye. Anti-VEGF therapy is thus a potential treatment for exudative macular degeneration and diabetic retinopathy. Methods: Previously described animal models of vascular leakage and ocular neovascularization, including the Miles assay, the rat corneal angiogenesis model, and the mouse retinopathy of prematurity (ROP) model, were used to study this drug. After these studies, a phase 1A single ascending dose study of intravitreal injections of the drug was performed in 15 patients with subfoveal choroidal neovascularization secondary to exudative age-related macular degeneration (AMD). Results: The Miles assay model showed almost complete attenuation of VEGF-mediated vascular leakage following addition of EYE001, and the corneal angiogenesis model also showed a significant reduction in neovascularization with EYE001. The ROP model showed inhibition of 80% of the retinal neovascularization compared with controls (P = 0.0001). The phase 1A safety study of patients with exudative AMD showed no significant safety issues related to the drug. Ophthalmic evaluation revealed that 80% of patients showed stable or improved vision 3 months after treatment and that 27% of eyes demonstrated a three-line or greater improvement in vision on the Early Treatment for Diabetic Retinopathy Study chart at this time. Conclusion: Anti-VEGF therapy is a promising new avenue for the treatment of neovascular diseases of the eye, including exudative macular degeneration and diabetic retinopathy. Preclinical data from studies with EYE001 support clinical evaluation of its efficacy in such diseases. This report is the first to describe administration of anti-VEGF therapy in humans for exudative macular degeneration and shows the safety of such therapy for single injections. Further clinical studies are necessary to determine the safety of multiple intravitreal injections of EYE001 and larger studies are needed to prove the efficacy of this novel, potentially therapeutic agent for neovascular AMD.

KW - Age-related macular degeneration

KW - Angiogenesis

KW - Pharmacologic intervention

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0036959644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036959644&partnerID=8YFLogxK

U2 - 10.1097/00006982-200204000-00002

DO - 10.1097/00006982-200204000-00002

M3 - Article

C2 - 11927845

AN - SCOPUS:0036959644

VL - 22

SP - 143

EP - 152

JO - Retina

JF - Retina

SN - 0275-004X

IS - 2

ER -